Bristol Myers Squibb psoriasis drug shows positive Phase III results
pharmafile | April 29, 2021 | News story | | Bristol-Myers Squibb, bristol myers squibb, pharma, pharma news, psoriasis, psoriasis treatment
Bristol Myers Squibb’s investigational deucravacitinib drug, for the treatment of moderate-to-severe plaque psoriasis, has shown positive results in two Phase III trials.
The POETYK PSO-1 and POETYK PSO-2 trials administered participants with the deucravacitinib treatment, a placebo, or apremilast – a pre-existing medication for psoriasis. It evaluated patients’ Psoriasis Area and Severity Index (PASI) 75 response, and a static Physician’s Global Assessment (sPGA) score of clear or almost clear skin.
It was shown that 58.7% of patients treated with deucravacitinib achieved PASI 75, versus 12.7% receiving placebo in the first trial, and 53.6% versus 9.4% respectively in the second trial.
For sPGA, 53.6% of patients treated with deucravacitinib achieved the highest sPGA scores (0/1), versus 7.2% of patients receiving placebo in the first trial. In the second trial, 50.3% of patients on deucravacitinib managed the highest sPGA scores, versus 8.6% on placebo.
In the secondary endpoint – deucravacitinib compared with apremilast – deucravacitinib was also found to be 23.6% and 13.4% more effective for PASI 75 in trials one and two respectively, and 21.5% and 16% more effective for the highest sPGA scores in each trial respectively.
In both trials – POETYK PSO-1, which enrolled 666 patients, and POETYK PSO-2, which enlisted 1,020 patients – participants not on placebo were given either 6mg of deucravacitinib once daily or 30mg of apremilast twice a day.
Psoriasis is a chronic disease that can impair physical health, quality of life and work productivity. At least 100 million people worldwide are impacted by some form of the disease, including around 14 million people in Europe and approximately 1.8 million people in the UK.
Between 80-90% of patients with psoriasis have plaque psoriasis, which is characterised by thickened reddish skin lesions, which are distinct round or oval plaques typically covered by dry silvery-white scales.
“The efficacy observed in these Phase III trials provides an opportunity to broaden the treatment choices in plaque psoriasis especially in patients who prefer an oral option,” said Professor Richard Warren, Consultant Dermatologist, Salford Royal NHS Foundation Trust, and Director of Dermatopharmacology Unit at The University of Manchester.
Jack Goddard
Related Content
LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …
Bristol Myers Squibb reports positive results for psoriatic arthritis treatment
Bristol Myers Squibb (BMS) has presented new data from its phase 3 POETYK PsA-1 trial, …
BioNTech and Bristol Myers Squibb collaborate on bispecific antibody for solid tumours
BioNTech and Bristol Myers Squibb (BMS) have entered a partnership to collaboratively develop and commercialise …
